US-based Dyax has appointed Mark Sawyer to the post of senior vice president and head of process sciences, technical operations and quality.
The role entails overseeing the manufacture and commercial supply of the protein DX-88. Additionally, he will guide Dyax's development process, formulation and clinical supply needs for early-stage molecules.
Brigitte Barbeau has been appointed to the newly created position of vice president, manufacturing at Canada-based Medicago. Barbeau will lead the company's manufacturing functions to accelerate the development of Medicago's H5N1 pandemic influenza vaccine and other vaccine candidates.
Bardeau has previously worked for GlaxoSmithKline on the commercial production of influenza vaccines and also has 20 years of experience in development, quality system design and quality assurance.
US-based Celator Pharmaceuticals has appointed Scott Jackson as the company's new CEO.
Jackson has experience in the pharmaceutical and biotechnology industry including positions in sales, marketing, and commercial development at Eli Lilly, ImClone Systems, Eximias Pharmaceuticals and YM BioSciences.
Willy De Greef has been appointed as secretary general of EuropaBio, replacing Johan Vanhemelrijck.
De Greef has experience in establishing biotechnology regulations and policies on a European and international level.
US-based Rib-X Pharmaceuticals has appointed Nancy Motola to the post of senior vice president of regulatory affairs. Motola will be responsible for ensuring that product development and business strategies are in line with global regulatory requirements.
Motola has over 20 years of experience in regulatory affairs and quality, at companies including Alexion Pharmaceuticals and Bayer.
Karin Hamberg has been appointed to the post of executive vice president for research and development at Denmark-based LifeCycle Pharma. In this role Hamberg will be responsible for drug delivery research, in addition to alliance and project management.
Prior to joining LifeCycle Pharma, Hamberg worked for 15 years at LEO Pharma, where she held various management positions within development and R&D project management.
US-based Noven Pharmaceuticals has appointed Peter Brandt as its new president and chief executive, succeeding interim CEO Jeffrey Eisenberg, who will remain on as executive vice president.
Brandt comes to Noven after 28 years with Pfizer, where he most recently held the post of president of US pharmaceutical operations.
US-based MacroGenics, a private biotechnology company specialising in the treatment of autoimmune disorders, cancers, and infectious diseases, has appointed Jean-Christophe Tellier as chief commercial officer and James Karrels as chief financial officer.
Dishman USA, a supplier of bulk pharmaceutical drugs, has appointed Fred Lint to the post of technical sales director.
